🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 13 of 114

  1. BAY94-9027

    Bayer HealthCare AG

    Hemophilia A

    phase 3 mab completed

    1 trial

  2. BCG (Tokyo 172) vaccine

    United Therapeutics Europe Ltd

    Tuberculosis Infection

    phase 3 mab terminated

    1 trial

  3. BCG VACCINE , JNJ-63723283, JNJ-17000139, JNJ-63723283

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  4. BCX4161

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  5. BCX7353

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    4 trials

  6. BCX7353 capsules

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  7. BCX7353 capsules

    Biocryst

    Hereditary Angioedema, HAE

    phase 3 small molecule completed

    1 trial

  8. BDP

    Teva Pharma GmbH

    Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  9. BDP HFA

    Teva Pharma GmbH

    Seasonal Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  10. BDP Nasal Aerosol

    Teva Pharma GmbH

    Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  11. BE1116

    CSL Behring GmbH

    Complex Cardiovascular Surgery With Cardiopulmonary Bypass

    phase 3 mab active

    1 trial

  12. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, BEZAFIBRATE LP 400 mg, BEFIZAL 200 mg, comprimé pelliculé, Placebo BEZAFIBRATE 200 mg

    Pari Pharma GmbH

    Subjects with PBC with a non-optimal response to UDCA.

    phase 3 small molecule active

    1 trial

  13. BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, placebo of bezafibrate

    Pari Pharma GmbH

    primary sclerosing cholangitis

    phase 3 small molecule active

    1 trial

  14. BELZUPACAP SAROTALOCAN, Placebo (Sham injection) to Belzupacap Sarotalocan solution for sham injection 0.0 mg/mL, BELZUPACAP SAROTALOCAN

    Aura Biosciences

    Primary Indeterminate Lesions or Small Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  15. BENDAFOLIN 10 mg/ml Injektionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FLUOROURACIL–EBEWE, 50 MG/ML, ROZTWÓR DO WSTRZYKIWAN I INFUZJI, Napabucasin

    The George Institute

    Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic.

    phase 3 small molecule active

    1 trial

  16. BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab

    Genmab A/S

    B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  17. BENDAMUSTINE HYDROCHLORIDE, PREDNISOLONE , CYCLOPHOSPHAMIDE, LENALIDOMIDE, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, Golcadomide, Golcadomide, PEGFILGRASTIM, Golcadomide, BENDAMUSTINE HYDROCHLORIDE, RITUXIMAB, LENALIDOMIDE, RITUXIMAB, VINCRISTINE SULFATE, LENALIDOMIDE, LENALIDOMIDE, CYCLOPHOSPHAMIDE, Golcadomide, DOXORUBICIN HYDROCHLORIDE

    Celgene Europe Limited

    Relapsed/Refractory Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  18. BEP(500)

    United Therapeutics Europe Ltd

    Stage I Testicular Non-Seminomatous Germ Cell Tumor

    phase 3 small molecule completed

    1 trial

  19. BETAMETHASONE, Placebo of fludrocortisone, HYDROCORTISONE HEMISUCCINATE, Placebo of hydrocortisone, FLUDROCORTISONE

    Pari Pharma GmbH

    Patients admitted to the ICU proven or suspected infection as the main diagnosis.

    phase 3 small molecule active

    1 trial

  20. BEVACIZUMAB, BEVACIZUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, Telisotuzumab adizutecan, Lonsurf 15 mg/6.14 mg film-coated tablets

    AbbVie Deutschland GmbH & Co. KG

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  21. BEVACIZUMAB, ERLOTINIB

    Fondazione Telethon ETS

    Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  22. BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, PF-08634404

    Pfizer Australia Pty Ltd

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  23. BEVACIZUMAB, PARACETAMOL , MK-2870, DEXAMETHASONE, BEVACIZUMAB , -, -, MK-2870, -

    Merck Sharp and Dohme

    Ovarian cancer recurrent

    phase 3 small molecule active

    1 trial

  24. BG00012

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  25. BGB-11417, BGB-11417 placebo, BGB-11417, BGB-11417, BGB-11417, Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    relapsed or refractory mantle cell lymphoma (R/R MCL)

    phase 3 small molecule active

    1 trial

  26. BGB-11417, Zanubrutinib, BGB-11417, Venclyxto 100 mg film-coated tablets, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  27. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    CLL

    phase 3 small molecule active

    1 trial

  28. BGB-16673

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    2 trials

  29. BGB-3111

    BeiGene

    Waldenström's Macroglobulinemia

    phase 3 small molecule completed

    1 trial

  30. BGB-43395

    BEONE MEDICINES AUS PTY LTD

    HR+/HER2- Breast Cancer

    phase 3 small molecule active

    1 trial

  31. BGF MDI 320/14.4/9.6 μg

    AstraZeneca

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 3 small molecule active

    1 trial

  32. BGF MDI 320/28.8/9.6 μg

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  33. BGF MDI HFO 320/14.4/9.6μg

    AstraZeneca

    COPD (Chronic Obstructive Pulmonary Disease)

    phase 3 small molecule completed

    1 trial

  34. BGJ398

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  35. BHV-7000, Placebo for BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

    phase 3 small molecule active

    1 trial

  36. BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000

    Biohaven Bioscience Ireland Limited

    Early Parkinson’s Disease

    phase 3 small molecule active

    1 trial

  37. BI 1015550, BI 1015550

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF)

    phase 3 small molecule active

    1 trial

  38. BI 1015550, Placebo matching BI 1015550, BI 1015550

    Boehringer Ingelheim

    Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

    phase 3 small molecule active

    1 trial

  39. BI 1015550, Placebo matching nerandomilast (BI 1015550)

    Boehringer Ingelheim

    Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

    phase 3 small molecule active

    1 trial

  40. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  41. BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  42. BI 201335

    Boehringer Ingelheim

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  43. BI 201335

    Boehringer Ingelheim

    Hepatitis C, Chronic

    phase 3 small molecule completed

    1 trial

  44. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  45. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  46. BI 456906, BI 456906, BI 456906, BI 456906, Placebo matching products 1 to 7 (pre-filled syringe, filling volume: 0.5 mL), BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  47. BI 456906, Placebo, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  48. BI 695501

    Boehringer Ingelheim

    Arthritis, Rheumatoid

    phase 3 small molecule completed

    2 trials

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.